Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ITOS 
Iteos Therapeutics Inc (ITOS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ITOS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.3
1 Year Target Price $10.3
| 3 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.37% | Avg. Invested days 32 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 448.68M USD | Price to earnings Ratio - | 1Y Target Price 10.3 |
Price to earnings Ratio - | 1Y Target Price 10.3 | ||
Volume (30-day avg) 6 | Beta 1.49 | 52 Weeks Range 4.80 - 17.63 | Updated Date 08/29/2025 |
52 Weeks Range 4.80 - 17.63 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date 2025-08-29 | When - | Estimate -0.8882 | Actual -1.81 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -18.49% | Return on Equity (TTM) -34.97% |
Valuation
Trailing PE - | Forward PE 12.56 | Enterprise Value -62501319 | Price to Sales(TTM) 12.78 |
Enterprise Value -62501319 | Price to Sales(TTM) 12.78 | ||
Enterprise Value to Revenue 1.26 | Enterprise Value to EBITDA 0.5 | Shares Outstanding 44205400 | Shares Floating 33237155 |
Shares Outstanding 44205400 | Shares Floating 33237155 | ||
Percent Insiders 0.98 | Percent Institutions 90.28 |
Upturn AI SWOT
Iteos Therapeutics Inc
Company Overview
History and Background
Iteos Therapeutics, Inc. (ITOS) is a biotechnology company focused on the discovery and development of next-generation cancer immunotherapies. Founded in 2011, it aims to harness the power of the immune system to fight cancer. A significant milestone was its IPO in 2020, which provided capital for clinical development.
Core Business Areas
- Drug Development: Iteos focuses on developing novel cancer immunotherapies targeting key immunosuppressive pathways within the tumor microenvironment.
- Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its drug candidates in various cancer types.
- Research and Discovery: Iteos engages in research and discovery activities to identify new targets and develop innovative therapeutic approaches.
Leadership and Structure
The leadership team consists of experienced executives in the biotechnology industry. The organizational structure is typical of a biotech company, with departments focused on research, development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- EOS-448 (anti-TIGIT antibody): EOS-448 is an antibody designed to block TIGIT, an inhibitory receptor on T cells and NK cells. It is currently in clinical trials for various solid tumors. Market share data is not yet available as it is still in development. Competitors include Roche (tiragolumab), Gilead and Arcus.
- Inupadenant (A2AR antagonist): Inupadenant is an adenosine A2A receptor antagonist in Phase 3 clinical trials targeting solid tumors. Market share data is not yet available as it is still in development. Competitors include Corvus Pharmaceuticals and AstraZeneca.
Market Dynamics
Industry Overview
The cancer immunotherapy market is a rapidly growing segment of the pharmaceutical industry, driven by advancements in understanding the immune system's role in cancer and the development of innovative therapies like checkpoint inhibitors and cell therapies.
Positioning
Iteos is positioned as a developer of next-generation cancer immunotherapies. Its competitive advantage lies in its focus on novel targets and its combination therapy approach.
Total Addressable Market (TAM)
The global cancer immunotherapy market is expected to reach hundreds of billions of dollars. Iteos is targeting specific segments within this market with its innovative therapies. TAM for checkpoint inhibitors and A2A antagonists is substantial and growing.
Upturn SWOT Analysis
Strengths
- Novel drug targets
- Strong intellectual property portfolio
- Experienced management team
- Strategic collaborations with pharmaceutical companies
Weaknesses
- Limited number of marketed products
- Reliance on clinical trial success
- High cash burn rate typical of development-stage biotechs
Opportunities
- Expanding clinical trial programs
- Potential for regulatory approvals
- Partnerships with larger pharmaceutical companies
- Expanding to new cancer indications
Threats
- Clinical trial failures
- Competition from other immunotherapy companies
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- GILD
- REGN
- MRK
- BMY
- AZN
- ROCHE.SW
Competitive Landscape
Iteos faces intense competition in the cancer immunotherapy market. Its competitive advantage lies in its novel targets and combination therapy approach, but it needs to demonstrate clinical efficacy to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Iteos's historical growth has been driven by the advancement of its drug candidates through clinical trials and strategic partnerships.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization efforts. Analyst estimates vary, but positive trial results could lead to significant revenue growth.
Recent Initiatives: Recent initiatives include expanding clinical trials for EOS-448 and inupadenant and exploring combination therapy approaches.
Summary
Iteos Therapeutics is a clinical-stage biotech company with a promising pipeline of novel cancer immunotherapies. Its success hinges on positive clinical trial outcomes and regulatory approvals. The company faces stiff competition, but its innovative approach and strategic partnerships could drive future growth. It's currently weak on revenue, and expenses are high but this is expected until clinical trials are over, and products are approved, and commercialized.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Financial databases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on available information and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Iteos Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-07-24 | President, CEO & Director Dr. Michel Detheux Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 173 | |
Full time employees 173 | |||
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.